Candriam Luxembourg S.C.A. Raises Stake in GW Pharmaceuticals PLC (GWPH)
Candriam Luxembourg S.C.A. boosted its position in GW Pharmaceuticals PLC (NASDAQ:GWPH) by 41.2% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 24,000 shares of the biopharmaceutical company’s stock after buying an additional 7,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in GW Pharmaceuticals PLC were worth $2,406,000 as of its most recent filing with the SEC.
Other large investors have also recently added to or reduced their stakes in the company. Karp Capital Management Corp purchased a new stake in GW Pharmaceuticals PLC during the first quarter worth $365,000. Pictet Asset Management Ltd. boosted its stake in GW Pharmaceuticals PLC by 81.1% in the first quarter. Pictet Asset Management Ltd. now owns 128,571 shares of the biopharmaceutical company’s stock worth $15,549,000 after buying an additional 57,578 shares in the last quarter. Nwam LLC purchased a new stake in GW Pharmaceuticals PLC during the first quarter worth $208,000. Eqis Capital Management Inc. purchased a new stake in GW Pharmaceuticals PLC during the first quarter worth $284,000. Finally, ING Groep NV boosted its stake in GW Pharmaceuticals PLC by 89.5% in the first quarter. ING Groep NV now owns 19,222 shares of the biopharmaceutical company’s stock worth $2,325,000 after buying an additional 9,078 shares in the last quarter. Institutional investors and hedge funds own 75.77% of the company’s stock.
GW Pharmaceuticals PLC (GWPH) opened at 100.52 on Thursday. GW Pharmaceuticals PLC has a 52 week low of $79.62 and a 52 week high of $137.88. The firm’s 50 day moving average price is $107.59 and its 200-day moving average price is $113.61. The stock’s market cap is $2.54 billion.
GW Pharmaceuticals PLC (NASDAQ:GWPH) last released its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.73) by $0.34. GW Pharmaceuticals PLC had a negative net margin of 1,384.41% and a negative return on equity of 28.80%. The business had revenue of $3.14 million during the quarter, compared to analyst estimates of $2.10 million. During the same period in the previous year, the firm posted ($0.05) EPS. Analysts expect that GW Pharmaceuticals PLC will post ($5.10) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This story was first posted by Watch List News and is the property of of Watch List News. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.watchlistnews.com/candriam-luxembourg-s-c-a-raises-stake-in-gw-pharmaceuticals-plc-gwph/1468843.html.
A number of equities research analysts recently weighed in on the company. Maxim Group set a $135.00 price target on GW Pharmaceuticals PLC and gave the stock a “buy” rating in a report on Monday. Zacks Investment Research cut GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Cantor Fitzgerald set a $208.00 price target on GW Pharmaceuticals PLC and gave the stock a “buy” rating in a report on Tuesday. BidaskClub raised GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. Finally, ValuEngine raised GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. Five analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. GW Pharmaceuticals PLC has an average rating of “Buy” and an average target price of $147.94.
GW Pharmaceuticals PLC Company Profile
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Want to see what other hedge funds are holding GWPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GW Pharmaceuticals PLC (NASDAQ:GWPH).
Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.